Stock TLSI TRISALUS LIFE SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights TriSalus Life Sciences, Inc.

Equities

TLSI

US89680M1018

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-06-26 pm EDT 		5-day change 1st Jan Change
5.76 USD +1.95% Intraday chart for TriSalus Life Sciences, Inc. +1.41% -31.83%
Jun. 03 TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial CI
May. 30 Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial
CI
TriSalus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Posts Q1 Revenue $6.5M, vs. Street Est of $5.9M
MT
TriSalus Life Sciences, Inc. Provides Sales Guidance for the Full Year of 2024
CI
TriSalus Life Sciences Obtains $50 Million Debt Facility
MT
TriSalus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
TriSalus Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Reports Q4 Revenue $5.7M
MT
TriSalus Life Sciences, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023; Provides Revenue Guidance for the Full Year 2024
CI
Haystack Oncology Enters A Research Collaboration with TriSalus Life Sciences to Evaluate Therapeutic Response and Provide Molecular Insights in Connection with the Clinical Development of TriSalus' SD-101
CI
TriSalus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Posts Q3 Revenue $5.2M
MT
TriSalus Life Sciences, Inc. Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma At the Society for Immunotherapy of Cancer Annual Meeting
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TLSI Stock
  4. News TriSalus Life Sciences, Inc.
  5. Highlights